Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Hemay005 in Moderate to Severe Plaque Psoriasis
NCT04102241Phase 2Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mufemilast in plaque psoriasis (4 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Proportion of subjects who have 75% or more reduction in PASI at 16 weeks. Started May 2019; status: completed.
02
Drugs
mufemilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04102241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102241.